Literature DB >> 34919793

[Is peritoneal dialysis the first-choice renal replacement therapy for patients waiting for a kidney transplant?]

Luca Nardelli1, Antonio Scalamogna2, Maurizio Gallieni3, Evaldo Favi4, Piergiorgio Messa1, Giuseppe Castellano1.   

Abstract

Kidney transplantation is the gold-standard treatment of end-stage renal disease. Receiving a pre-emptive transplant ensures the best survival for both the recipient and the allograft. However, due to an overwhelming discrepancy between available donors and patients on the transplant waiting list, the vast majority of transplant candidates require prolonged periods of dialytic therapy before transplant. Peritoneal dialysis and hemodialysis have been traditionally considered as competitive renal replacement therapies. This dualistic vision has been recently questioned by emerging evidence suggesting that an individualized and flexible approach may be more appropriate. Tailored and cleverly planned shifts between different modalities, according to the patient's needs, represents the best option. Remarkably, recent data seem to support the use of peritoneal dialysis over hemodialysis in patients waiting for a kidney transplant. In this specific setting, the perceived advantages of PD are better overall recipient survival and quality of life, longer preservation of residual renal function, lower incidence of delayed graft function and reduced cost. Copyright by Società Italiana di Nefrologia SIN, Rome, Italy.

Entities:  

Keywords:  delayed graft function; hemodialysis; kidney transplant waiting-list; peritoneal dialysis; quality of life; residual renal function

Mesh:

Year:  2021        PMID: 34919793

Source DB:  PubMed          Journal:  G Ital Nefrol        ISSN: 0393-5590


  1 in total

1.  Incremental peritoneal dialysis allows to reduce the time spent for dialysis, glucose exposure, economic cost, plastic waste and water consumption.

Authors:  Luca Nardelli; Antonio Scalamogna; Elisa Cicero; Giuseppe Castellano
Journal:  J Nephrol       Date:  2022-09-20       Impact factor: 4.393

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.